The Management Team
Meet our management team of highly skilled professionals who bring extensive knowledge within stem cell therapies.
Cell to Cure brings extensive experience in the research, development and commercialisation of live cell-based therapies. Our collective expertise spans all critical areas required to develop and advance cell therapy from bench to bedside.
Fields of Expertise
Cell biology and
translational research
GMP-compliant manufacturing of
cell-based products
Quality assurance and regulatory affairs
Clinical development across multiple disease indications
Business development and corporate management
With this solid foundation and extensive knowledge, Cell to Cure is well-positioned to foster innovation and bring potentially valuable therapies to patients.
Jens Kastrup
Professor, MD, DMSc, FESC
CEO & Clinical Director
Jens has a long and well-established career within cardiology and is internationally recognised as a leading expert in stem cell-based treatment of heart disease. He was the founder of the Cardiology Stem Cell Centre in the Heart Centre, Rigshospitalet University Hospital, Copenhagen Denmark.
Jens is one of the original inventors of the technology behind Cell to Cure ApS. He has been heading stem cell research for more than 20 years, has several Research Awards and more than 400 publications.
Annette Ekblond
M.Sc., Ph.D.
Director of Product Development & Qualified Person
Annette has extensive experience with product development and quality management, aligning all stages of product development from early research to clinical-grade manufacturing and control, with regulatory frameworks for Advanced Therapy Medicinal Products.
Annette is one of the original inventors of the technology behind Cell to Cure and has been head of the Cardiology Stem Cell Centre laboratory, Rigshospitalet University Hospital for 11 years. Since 2015, Annette has also served as Qualified Person.
Mandana Haack-Sørensen
M.Sc., Ph.D.
Director of Manufacturing
Mandana is one of the original three inventors of the technology behind Cell to Cure and together with them, she has developed the production technology behind Cell to Cure.
Mandana oversees all Cell to Cure’s manufacturing, storage and distribution processes and spearheads development of the production technology central to Cell to Cure’s IP base. She is in charge of our GMP manufacturing of stem cell-based ATIMP products for research, clinical and commercial use.
Martin Roland Jensen
M.Sc. Ph.D.
Commercial Director
Martin has extensive experience from founding and establishing several biotechnology and pharmaceutical companies, as well as extensive pharmaceutical project management and regulatory experience from running sciences- and technology-based companies and projects.
Martin is responsible for all commercial aspect of Cell to Cure, including business development, company structure, management, IP, funding and finance.
